C4 Therapeutics, Inc.

CCCCNASDAQHealthcare● Active

$3.73

+$0.14(+3.76%)

Market Cap$308531275

P/E Ratio—

52W High$4.598

52W Low$1.36

Avg Volume2.9M

Open$3.62

Beta2.93

Overview

C4 Therapeutics, Inc. (CCCC) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

CCCC · free cash flow · updated Jun 9, 2026

Core FCF metrics

CCCC · FCF · TTM · margin & CAGR

Free cash flow was −$99.3M for FY2025 (fiscal year ending 2025-12-31), down 52.0% year-over-year The FCF margin was -276.2%.

FY2025 Free Cash Flow−$99.3M▼ -52.0% YoY

Trailing 12M (TTM)−$96.0Mtrailing 4 quarters sum

FCF Margin-276.2%−$99.3M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 9, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

CCCC · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$98.7M(1M)−$99.3M▼ 52.0%-276.2%

FY2024−$65.2M(0M)−$65.3M▲ +39.8%-183.6%

FY2023−$106.8M(2M)−$108.5M▲ +2.6%-523.0%

FY2022−$105.9M(5M)−$111.4M▼ 26.3%-358.4%

FY2021−$87.0M(1M)−$88.2M▼ 30.0%-192.7%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

CCCC · P/FCF · FCF yield · FCF per share

C4 Therapeutics, Inc. (CCCC) reported negative free cash flow of −$0.10B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

CCCC · cash flow statement · operating / investing / financing

For FY2025, C4 Therapeutics, Inc. generated −$98.7M in operating cash flow and spent 1M in capital expenditures, yielding −$99.3M in free cash flow.

Operating Activities

−$98.7M

Cash from core business operations

2025-12-31

Investing Activities

−$8.6M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$126.4M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$98.7M) − |CapEx| (1M) = FCF (−$99.3M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

CCCC vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

C4 Therapeutics, Inc.YOU

CCCC

−$99.3M-52.0%-276.2%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

C4 Therapeutics, Inc. (CCCC) reported free cash flow of −$99.3M for FY2025 (fiscal year ending 2025-12-31), down 52.0% year-over-year. The FCF margin was -276.2%.

Based on available data, C4 Therapeutics, Inc. has maintained positive free cash flow for at least 1 fiscal year(s). FCF peaked at $54.3M in FY2019.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

CCCC free cash flow · 8 questions

C4 Therapeutics, Inc. free cash flow was −$99.3M for FY2025, down 52.0% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$96.0M.

CCCC free cash flowCCCC FCFCCCC FCF 2025CCCC free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · C4 Therapeutics, Inc. · C4 Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 9, 2026